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Background

Results (cont.)

• One important prognostic indicator in pediatric leukemia is minimal residual
disease (MRD) detected at the end of induction chemotherapy.
• Compared to having no MRD detected (MRD-), detecting any level of MRD in
the bone marrow (BM) at the end of induction (MRD+) is associated with:
• Increased risk of relapse

*Gated from ‘CD8+ T cells’

*Gated from ‘Naïve T cells

• Poorer overall survival
• Discovering differences between these patients, specifically in T cell subsets
such as memory CD8+ T cells and T memory stem cells (Tscm) could lead to
new targets for cancer therapy and improvement in treatment for higher risk
disease.
• Objective: To determine differences in T cell populations in human leukemia
in patients with MRD+ vs MRD- disease after induction chemotherapy.

Results
• For all patients, both MRD+ and MRD-, the mean live cell percentages were not
different between diagnosis and D29 (76.9% vs 85.1%, p=0.111).

Conclusions

• CD3+, CD4+, and CD8+ T cells were all higher at D29 (CD3+ - 2.1% vs 6.5%, p=0.011;
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CD4+

- 1.0% vs 2.7%, p=0.044;

CD8+

-0.8% vs 2.7%, p=0.018).

• Naïve T cells increased from diagnosis to D29 (0.4% vs 3.4%, p=0.009).
• Tscm were also elevated at D29 (0.01% vs 0.08%, p=0.042).

Methods
• Samples were from 8 pediatric patients with premature B cell acute
lymphoblastic leukemia (pre-B ALL) from BM.
• 4 patients were MRD+ after induction and 4 patients were MRD-.
• Timepoints were at diagnosis and day 29 (D29) of induction chemotherapy.
• Flow cytometric analysis of cytotoxic memory T cell populations was
performed and analyzed using descriptive statistics and the t-test.

• When the patients were sub-grouped based on MRD status, similar differences
were seen in the MRD- group between diagnosis and D29 (CD3+ - 2.2% vs 7.8%,
p=0.039; CD4+ - 0.8% vs 4.0%, p=0.035; CD8+ - 1.1% vs 3.3%, p=0.073; Naïve- 0.4%
vs 3.8%, p=0.039; Tscm- 0.02% vs 0.1%, p=0.037).
• In the MRD+ subgroup, none of the previously described differences were

• Recovery of immune function is anticipated after induction
chemotherapy for pre-B ALL.
• Our data demonstrate the expected increase in T cell subsets in patients
with MRD- BM at D29 but not in patients with MRD+ BM.
• The discovery of poorer immunological recovery in MRD+ patients
requires additional study to determine what makes MRD+ disease
different.

detected (CD3+ - 2.0% vs 5.1%, p=0.197; CD4+ - 1.1% vs 1.4%, p=0.644; CD8+ - 0.6%

• This could introduce new immunotherapy targets in human leukemia.

vs 2.17%, p=0.175; Naïve- 0.5% vs 2.95%, p=0.173; Tscm- .004% vs 0.02%,
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p=0.355).
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